Field of expertise
Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing. We offer services in the following fields:
Genetic Toxicology
We have extensive experience and knowhow in the field of Genetic Toxicology. We often combine our unique ToxTracker assay with a range of extended protocols and additional assays to unravel the underlying mechanism of genotoxicity and predict the outcomes in the regulatory in vitro and in vivo genotoxicity assays.
Reproductive Toxicology
By combining our expertise in stem cell technologies and reporter systems, we have generated ReproTracker, an in vitro assay that is able to visualise key processes in the early embryonic development. The assay can be applied to assess developmental toxicology in the early phases of drug development.
Mechanistic Toxicology
All assays that are developed at Toxys are aimed at understanding the mechanism underlying toxicity. We believe that this mechanistic understanding is key to translate the results from in vitro test systems to a relevance for humans. These mechanism-based test systems can be particularly useful in an Adverse Outcome Pathway (AOP) approach for both genotoxic and non-genotoxic carcinogens and in the development of an Integrated Approach to Testing and Assessment (IATA).
Happy Customers
We work together with a growing number of customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups. We offer unique in-house screening capabilities combined with the responsiveness and flexibility found only in smaller companies. Please read what some of our customers said about working together:
"The differentiation between aneugens and clastogens is important in the hazard assessment of our pharmaceutical compounds. ToxTracker ACE conveniently combines the relevant endpoints to be able to do this"
“As a modern safety laboratory requiring mechanistic insights into mammalian toxicology, we adopted ToxTracker and installed the assay in-house. The expertise, training and support provided by Toxys for the technology transfer were excellent resulting in a seamless set-up of the assay in our facilities. In addition, we have had terrific reactivity from Giel and his team with our questions.”
"The ToxTracker assay is an excellent tool to evaluate the genotoxic potential of compounds, generating great additional value by dissecting the underlying genotoxic mechanisms, and thereby better assess the relevance of the genotoxic response in a fast and cost-efficient manner.”
“In regulatory assessment of carcinogenic or germ cell mutagenic risk, it is becoming increasingly important to understand mode of action, and not just rely on weight of negative evidence from in vivo genotoxicity studies to overrule positive in vitro genotoxicity results. To this end, there is increasing demand for integrated mechanism-based assays like ToxTracker as essential components in the development of safe and specific drugs or products.”
"Orion has worked successfully with Toxys on a couple of occasions. We are happy with the open communication which makes planning the experiments and interpreting the results easy and straightforward. The assay is excellent follow-up for our in-house micronucleus test to reveal the mode-of-action and hence validate or in-validate the borderline positive/negative dilemma."
“A succesful genotoxicity screening strategy is always dependent on the availability of mechanism of action data, as this will provide a link towards risk assessment. The Toxtracker assay is able to provide this relevant information fast and reliable so that the medicinal chemist is able to drive his chemistry plan into the safe zone.”
"Mechanism-based screening assays like the ToxTracker can make a valuable contribution to the routine safety compliance screening of our products"
“The expertise at Toxys is clear when you discuss results. The proactive team works hard to generate results within the timelines"
Toxys is selected as one of the FD Gazelles of 2020!
Toxys is very proud to announce that we have been selected as one of the FD Gazelles of 2020! The prestigious Gazelle awards are presented by the Dutch Financial Times (Het Financieele Dagblad) to fast-growing and financially successful companies in the Netherlands over the last...
Latest publication about aneugen versus clastogen evaluation and oxidative stress-related MOA
Check out our latest publication "Aneugen versus clastogen evaluation and oxidative stress-related mode-of-action assessment of genotoxic compounds using the ToxTracker reporter assay" published recently in Toxicological Sciences. This paper highlights the extended versions of the ToxTracker assay: ToxTracker ACE and ToxTracker AO. ToxTracker ACE (Aneugen Clastogen...
We are happy to launch ToxPlot: a unique software package for ToxTracker data analysis
We are happy to launch ToxPlot: a unique software package for ToxTracker data analysis. ToxPlot is an ideal add-on for ToxTracker that further increases the value of the assay. ToxPlot allows for extensive data analysis, unbiased data interpretation, automated report generation and secure data storage....
ReproTracker Webinar: introducing our novel in vitro developmental toxicity assay
On the 3rd of September, we hosted a webinar introducing ReproTracker, our novel in vitro developmental toxicity assay. Dr. Giel Hendriks, CEO of Toxys and Sabine Hartvelt, Junior Scientist at Toxys, discussed the challenges in reproductive toxicology and why ReproTracker was developed, along with its...
Toxys newsletter Summer 2020
Here you can view our newsletter from Summer 2020 ...
Toxys appoints Susan Swarte as new non-executive Board member
Leiden, The Netherlands. July 14, 2020 - Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative in vitro toxicity screening solutions to identify carcinogenic and other hazardous properties of compounds for the pharmaceutical, chemical, cosmetics and food industry. Today, Toxys...
Webinar: A highly quantitative in vitro method for mechanistic genotoxicity screening
On the 12th of May our recorded webinar with our partners at Miltenyi Biotech, introducing our in vitro genotoxicity assay, ToxTracker®, its opportunities, advantages and challenges faced when using this assay for mechanistic toxicity testing, was released. We also highlight the potential of using reliable flow...
Toxys signs agreement with BioPartner Leiden for new laboratory
Leiden, The Netherlands. May 5, 2020 - Toxys is an innovative Dutch biotech company that develops unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. Today, Toxyssigned an agreement with BioPartner Leiden for its new laboratory facilities. In spring...
ToxTracker webinar with user applications now available!
On the 18th of March our webinar on ToxTracker, including use applications for the Fragrance and Flavour industry and Agro-Chemical industry has been held. During this webinar, our new assays, ReproTracker and TubulinTracker, were also launched. The webinar can be found at our dedicated website for all...
COVID19 Contingency Planning and Continuity of Project Delivery from Toxys
Toxys has been monitoring the global corona virus outbreak since the beginning of this year and is updating business continuity plans daily. We want to assure you that we remain dedicated to provide high quality services to our clients while also protecting the health of...
